
Annesha White, Pharm.D., M.S., Ph.D., and Fredrick Manasseh, Pharm.D., MBA, BCGP, explain where AI helps managed care pharmacy, where bias creeps in and what skills pharmacists need to oversee it.

Annesha White, Pharm.D., M.S., Ph.D., and Fredrick Manasseh, Pharm.D., MBA, BCGP, explain where AI helps managed care pharmacy, where bias creeps in and what skills pharmacists need to oversee it.

Speakers and researchers at this year's meeting in San Diego focused on drug pricing policy, getting savings to patients at the pharmacy counter and keeping people in charge of AI.

MassHealth's Katelyn Meyer, Pharm.D., says mandatory coverage, young patients and an unpredictable FDA make planning for new specialty drugs a challenge.

As pulmonary fibrosis treatment options grow, Rachael Prusi of Prime Therapeutics says health plans should lean on guidelines and strong case management.

Patients with pulmonary fibrosis wait about two years for a diagnosis. Rachael Prusi of Prime Therapeutics explains how health plans can find them sooner.

Hiva Pourarsalan at AMCP Nexus explains how MFP shifts Medicare drug pricing, disrupting rebates and contracting and forcing payers to rethink formularies.

EHRs miss many cancer deaths. Linking electronic health records with claims and third‑party death data sharply improves accuracy, Tempus reports at AMCP Nexus.

Managed care leaders should vet AI tools before use and recheck them over time, and pharmacists need AI literacy, according to two AMCP Nexus 2026 presenters.

AI is speeding up managed care pharmacy work, but two pharmacists say human review remains key when tools affect patients' access to medications.

Prime Therapeutics' Pat Gleason, Pharm.D., outlined T1D screening gaps for plans and his priorities as incoming AMCP president.

Sempre Health CEO Anurati Mathur says affordability dollars should reach patients on every fill, and reversed claims show plans when they don’t.

Based on her findings, Mathur shared members in a UPMC affordability program were more adherent to heart drugs, with fewer ER visits and no significant rise in total cost of care.

A Cencora analysis of 32 pre-approval products found more than 60% of payer engagement with PIE resources came more than 90 days after posting.

AMCP leaders say PBM reform, new drug pricing models and AI will shape this week’s Nexus meeting in San Diego.

Milliman’s Jennifer Cruz says plans are losing rebates because of steep price discounts negotiated under the Inflation Reduction Act. but that they need to be sure that renegotiation of rebate guarantees doesn’t get too broad.

Pharmacy benefit managers are approaching health plans with value-based contracts that consider lower costs on the medical benefit of the insurance, says Jennifer Cruz of Milliman.

Almost 3,000 managed care pharmacy leaders attended the Academy of Managed Care Pharmacy (AMCP) Nexus meeting, which was held last week at the Gaylord National Resort and Convention Center in National Harbor, Maryland.

Milliman's Jennifer Cruz, Pharm.D., said health plans should be able to track rebates to their book of business and have strong audit rights.

Prior authorization using integrated medical claims data helps diabetes patients get medications faster, with two-thirds processed automatically by July 2025 in this Prime Therapeutics analysis.

Prime Therapeutics executives discuss specialty drug trends at AMCP Nexus. Key areas include autoimmune therapies, multiple sclerosis treatments, and emerging cell and gene therapy challenges for payers.

AI revolutionizes member health risk identification, outperforming traditional models by integrating diverse data for proactive care in managed care settings.

Cardiovascular, Renal and Metabolic Conditions Increasingly Prevalent, Expensive for Medicare Fee-For-Service Population

'It just knows black or white; it does not know the gray in between...humans have to fill that gray in between.'

Bispecific T-cell engagers demonstrate lower total costs and reduced cytokine release and neurotoxicity rates compared with CAR T therapy for patients with follicular lymphoma.

Payers and providers are using real-world data to identify high-performing treatment centers, reduce administrative bottlenecks, and support value-based contracting arrangements.

New data reveals a rising trend in generalized anxiety disorder (GAD) prevalence among U.S. adults, emphasizing the need for improved diagnosis and treatment.

An abstract presented at AMCP Nexus 2025 showed that Medicaid drug spend in 10 states in FY 2023 was approximately equal to or less than the national drug spending rate of 14%.

Former House Speaker Paul Ryan called for evidence-based reforms, risk pools and premium support models for Medicare, to fix the nation’s strained healthcare system.

Panelists at AMCP’s policy summit debated PBM reform, disagreeing on spread pricing ethics and rebate transparency while discussing costs, risks, and whether current contracting models benefit patients.

A study at AMCP Nexus 2025 reveals how drug rebates and net prices influence insurance coverage for specialty drugs, impacting patient access.